Moderna to sue Pfizer, BioNTech over patent infringement

In a statement, Moderna alleged that Pfizer, and its German partner BioNTech, copied "groundbreaking technology" developed by the company prior to the Covid-19 pandemic.

ADVERTISEMENT
Image
Jarryd Jaeger Vancouver, BC
ADVERTISEMENT

On Friday, Moderna announced that they would be seeking damages through a lawsuit against Covid-19 vaccine competitor Pfizer and its partner BioNTech, alleging that the companies engaged in patent infringement.

In a statement, Moderna alleged that Pfizer, and its German partner BioNTech, copied "groundbreaking technology" developed by the company prior to the Covid-19 pandemic.

Among the technology in question are those relating to ensuring mRNA from the vaccine can enter the body without triggering a negative immune response, and the encoding of the full-length spike protein in a lipid nanoparticle formulation for a coronavirus, such as MERS-CoV.

Both technologies were developed by the company years before the pandemic began, and well before Moderna's collaboration with the National Institutes of Health.

"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission," the company's Chief Legal Officer, Shannon Thyme Klinger, said.

She went on to explain that Moderna would like to see Pfizer and BioNTech compensate them for their "ongoing use" of the aforementioned technologies, but only outside of AMC 92 countries, where their patents are not enforced. They reiterated that the goal of the lawsuit is not to see Pfizer-BioNTech's vaccine removed from the market.

Additionally, Moderna stated that they are not seeking damages from sales in AMC 92 countries, nor from any time prior to March 8, 2022, as per their patent pledge.

"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the Covid-19 pandemic," said Moderna CEO Stéphane Bancel.

"This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck."

He went on to explain that the company is "using our mRNA technology platform to develop medicines that could treat and prevent infectious diseases like influenza and HIV, as well as autoimmune and cardiovascular diseases and rare forms of cancer."

ADVERTISEMENT
ADVERTISEMENT
Sign in to comment

Comments

Powered by StructureCMS™ Comments

Join and support independent free thinkers!

We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.

Support The Post Millennial

Remind me next month

To find out what personal data we collect and how we use it, please visit our Privacy Policy

ADVERTISEMENT
ADVERTISEMENT
By signing up you agree to our Terms of Use and Privacy Policy
ADVERTISEMENT
© 2024 The Post Millennial, Privacy Policy